Skip to main content

Table 2 Patient incidence of motesanib-related adverse events

From: Safety and pharmacokinetics of motesanib in combination with gemcitabine and erlotinib for the treatment of solid tumors: a phase 1b study

 

Motesanib + Gemcitabine + Erlotinib

(100 mg QD)

Motesanib + Erlotinib

(150 mg QD)

Patient Incidence

Motesanib

50 mg QD

(n = 7)

Motesanib

100 mg QD

(n = 8)

Motesanib

125 mg QD

(n = 10)

Motesanib

75 mg BID

(n = 9)

Motesanib

100 mg QD

(n = 7)

Motesanib

125 mg QD

(n = 7)

Any adverse event, n

3

8

9

7

7

6

Adverse events of grade 3, na

0

3

6

3

3

4

   Diarrhea

0

1

1

0

2

1

   Nausea

0

0

3

1

0

0

   Vomiting

0

1

2

0

0

0

   Fatigue

0

1

0

0

0

2

   Tumor necrosis

0

0

0

1

1

0

   Deep vein

      

thrombosis

0

0

2

0

0

0

   Abnormal liver

      

function test

0

1

0

0

0

1

   Neutropenia

0

1

0

0

1

0

Adverse events of grade 4, n

      

   Pulmonary

1

0

2

1

0

0

embolism

0

0

2

0

0

0

   Febrile neutropenia

1

0

0

0

0

0

   Neutropenia

0

0

0

1

0

0

Adverse events of interest and highest (worst) grade, n

      

   Hypertension

0

0

0

2

1

2

Grade 3

0

0

0

0

0

1

   Thrombophlebitis (all grade 3)

0

0

1

0

0

0

   Gallbladder toxicity

0

0

2b

0

1c

0

Grade 3

0

0

1

0

0

0

   Hemorrhagic events

0

0

1d

0

1e

0

Grade 3

0

0

1

0

0

0

   Cardiac toxicity (all grade 3)

0

1f

0

0

0

0

  1. BID = twice daily; QD = once daily
  2. aFor motesanib-related adverse events only those grade 3 events are listed that occurred in ≥ 2 patients.
  3. bCholecystitis (n = 1; grade 3) and gallbladder enlargement (n = 1; grade 1)
  4. cGallbladder enlargement (grade 2)
  5. dSubdural hematoma
  6. eEpistaxis (grade 1)
  7. fCongestive heart failure and pulmonary edema